HeartSciences Inc. (NASDAQ:HSCS) Sees Large Decline in Short Interest

HeartSciences Inc. (NASDAQ:HSCS) was the target of a large drop in short interest in July. As of July 15th, there was short interest totaling 77,601 shares, a drop of 37.2% from the June 30th total of 123,640 shares. Based on an average daily trading volume, of 58,703 shares, the short-interest ratio is presently 1.3 days. Currently, 2.6% of the company’s stock are sold short.

HeartSciences Stock Up 4.8%

Shares of HeartSciences stock traded up $0.10 during trading on Friday, reaching $2.18. The company’s stock had a trading volume of 40,317 shares, compared to its average volume of 996,999. HeartSciences has a 1-year low of $1.63 and a 1-year high of $3.93. The company has a 50-day simple moving average of $2.30 and a two-hundred day simple moving average of $2.47. The company has a market cap of $8.50 million, a price-to-earnings ratio of -0.55 and a beta of 1.78.

HeartSciences (NASDAQ:HSCS) last announced its earnings results on Thursday, July 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.22). As a group, analysts anticipate that HeartSciences will post -3.02 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Trading of HeartSciences

A hedge fund recently raised its stake in HeartSciences stock. DRW Securities LLC boosted its stake in shares of HeartSciences Inc. (NASDAQ:HSCS) by 13.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 95,065 shares of the company’s stock after purchasing an additional 11,455 shares during the period. DRW Securities LLC owned approximately 2.99% of HeartSciences worth $294,000 at the end of the most recent reporting period. 17.24% of the stock is owned by institutional investors.

More HeartSciences News

Here are the key news stories impacting HeartSciences this week:

• Positive Sentiment: Maxim Group raised its FY2028 EPS forecast to a loss of $2.13 per share from a loss of $2.21, suggesting the analyst expects HeartSciences’ long-term losses to narrow more quickly than previously anticipated. Estimates for Q1-Q4 2028 were also generally improved. Maxim Group EPS estimate revisions
• Neutral Sentiment: The revisions were mixed overall. Maxim maintained a FY2027 loss forecast of $2.98 per share, while slightly improving several 2028 quarterly estimates. However, all of the published forecasts still call for HeartSciences to remain unprofitable through FY2028. HeartSciences analyst estimates
• Negative Sentiment: Maxim lowered its FY2027 EPS forecast to a loss of $2.98 from $2.93 and reduced estimates for Q1-Q3 2027 and Q4 2027. These cuts indicate weaker near-term expectations and may be weighing on sentiment toward HSCS. Maxim Group 2027 EPS estimate reductions
• Negative Sentiment: HeartSciences previously reported a quarterly loss of $0.88 per share, worse than the $0.66 analyst consensus. With analysts still projecting a full-year loss of approximately $3.02 per share, the company’s ongoing cash needs and path to profitability remain key risks for investors.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.